Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-acting injectable cabotegravir for the prevention of HIV infection
Meredith E. Clement, Ryan Kofron, Raphael J. Landovitz
Current Opinion in HIV and AIDS (2019) Vol. 15, Iss. 1, pp. 19-26
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Approved Nanomedicine against Diseases
Yuanchao Jia, Yuxin Jiang, Yonglong He, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 774-774
Open Access | Times Cited: 62
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
Paul Thoueille, Eva Choong, Matthias Cavassini, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 77, Iss. 2, pp. 290-302
Open Access | Times Cited: 94
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
Suyash Deodhar, Brady Sillman, Aditya N. Bade, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115009-115009
Open Access | Times Cited: 26
PrEP distribution in pharmacies: a systematic review
Caitlin E. Kennedy, Ping Teresa Yeh, Kaitlyn Atkins, et al.
BMJ Open (2022) Vol. 12, Iss. 2, pp. e054121-e054121
Open Access | Times Cited: 36
New drug approvals for 2021: Synthesis and clinical applications
Shuo Yuan, Dan-Shu Wang, Hui Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114898-114898
Closed Access | Times Cited: 32
Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension
Moses R. Kamya, Laura B. Balzer, James Ayieko, et al.
The Lancet HIV (2024) Vol. 11, Iss. 11, pp. e736-e745
Closed Access | Times Cited: 8
Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19
Steven Shoptaw, David Goodman‐Meza, Raphael J. Landovitz
AIDS and Behavior (2020) Vol. 24, Iss. 7, pp. 2013-2016
Open Access | Times Cited: 45
Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
Urvi M. Parikh, Catherine A. Koss, John W. Mellors
Current HIV/AIDS Reports (2022) Vol. 19, Iss. 5, pp. 384-393
Open Access | Times Cited: 26
Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates
Fernanda P. Pons‐Faudoa, Nicola Di Trani, Simone Capuani, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 702
Closed Access | Times Cited: 15
Current drugs for HIV-1: from challenges to potential in HIV/AIDS
Peng Yuan, Yanjun Zong, Dongfeng Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options
Connie Celum, Jared M. Baeten
Cell Host & Microbe (2020) Vol. 27, Iss. 4, pp. 502-506
Open Access | Times Cited: 39
Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates
Fernanda P. Pons‐Faudoa, Antons Sizovs, Kathryn A. Shelton, et al.
Advanced Therapeutics (2020) Vol. 4, Iss. 3
Open Access | Times Cited: 39
How to Have Sex in an Epidemic Redux: Reinforcing HIV Prevention in the COVID-19 Pandemic
Peter A. Newman, Adrian Guţă
AIDS and Behavior (2020) Vol. 24, Iss. 8, pp. 2260-2264
Open Access | Times Cited: 34
Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey
Ashwin Yajaman Belludi, Allison M. McFall, Sunil S. Solomon, et al.
PLoS ONE (2021) Vol. 16, Iss. 2, pp. e0247352-e0247352
Open Access | Times Cited: 30
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 3, pp. 510-520
Open Access | Times Cited: 21
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Urvi M. Parikh, John W. Mellors
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 213-221
Open Access | Times Cited: 20
Preferences for PrEP modalities among gay, bisexual, and other men who have sex with men from Brazil, Mexico, and Peru: a cross-sectional study
Thiago S. Torres, Alessandro Nascimento, Lara E. Coelho, et al.
Therapeutic Advances in Infectious Disease (2023) Vol. 10
Open Access | Times Cited: 13
Intention to Use Different Formulations of Longer Acting HIV Pre-Exposure Prophylaxis Among Transgender and Gender Expansive Individuals: The Roles of Social Vulnerability and Medical Mistrust
Phillip W. Schnarrs, Julie A. Zuñiga, Gabrielle Benitez, et al.
AIDS Patient Care and STDs (2024) Vol. 38, Iss. 2, pp. 51-60
Closed Access | Times Cited: 4
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy
Jenna Yager, Peter L. Anderson
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 6, pp. 463-474
Closed Access | Times Cited: 31
Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most
Morgan M. Philbin, Sadie Bergen, Carrigan Parish, et al.
AIDS and Behavior (2021) Vol. 26, Iss. 4, pp. 1260-1269
Open Access | Times Cited: 26
PrEP service delivery preferences of black Cis-gender women living in the Southern United States
Latesha Elopre, Alexander Boutwell, Bretia Gordon, et al.
AIDS and Behavior (2022) Vol. 26, Iss. 11, pp. 3469-3479
Open Access | Times Cited: 19
Promises and challenges: cabotegravir for preexposure prophylaxis
Matthew A. Spinelli, Beatriz Grinsztejn, Raphael J. Landovitz
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 186-191
Open Access | Times Cited: 18
Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis
Wenjing Wang, Shengnan Zhao, Yaxin Wu, et al.
JMIR Public Health and Surveillance (2023) Vol. 9, pp. e46767-e46767
Open Access | Times Cited: 10
An Open Letter on Advancing HIV prevention: Augmenting an ecosystem-based approach to understand prevention decision-making
Nishan Gantayat, James A. Baer, Alok Gangaramany, et al.
Gates Open Research (2025) Vol. 8, pp. 73-73
Open Access
Page 1 - Next Page

Scroll to top